Skip to main content

Table 3 Baseline patient demographics and clinical characteristics

From: The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics

Parameter rhPTH(1-84)
(n=134)
Conventional Therapy
(n=603)
Analysis Populationa
(N=737)
Age, mean ± SD, y 47.9±14.22 49.3±16.91 49.1±16.45
Age, category, n (%), y
 0–17 3 (2.2) 24 (4.0) 27 (3.7)
 18–39 34 (25.4) 135 (22.4) 169 (22.9)
 40–64 81 (60.4) 336 (55.7) 417 (56.6)
 ≥65 16 (11.9) 108 (17.9) 124 (16.8)
Women, n (%) 115 (85.8) 472 (78.3) 587 (79.6)
Race, white, n (%) 112 (83.6) 508 (84.2) 620 (84.1)
BMI, mean ± SD, y
 <18b 17.2±0.46 19.6±6.07 19.3±5.73
 ≥18c 31.1±9.48 29.7±7.32 30.0±7.72
Primary cause of hypoparathyroidism, n (%)
 Surgery 85 (63.4) 462 (76.6) 547 (74.2)
 Idiopathic 12 (9.0) 46 (7.6) 58 (7.9)
 Genetic and autoimmune 12 (9.0) 44 (7.3) 56 (7.6)
 Radiation 0 1 (0.2) 1 (0.1)
 Unknown/other/missing 25 (18.7) 50 (8.3) 75 (10.2)
Primary cause for thyroid surgery
 Thyroid cancer, n (%) 37 (56.1) 244 (60.7) 281 (60.0)
Duration of hypoparathyroidism, mean ± SD, yd 9.0±10.27 10.3±11.53 10.1±11.34
  1. BMI body mass index, rhPTH(1-84) recombinant human parathyroid hormone (1-84)
  2. aBaseline is defined as the assessment at enrollment (visit 1); 737 patients as of 30 June 2019
  3. brhPTH(1-84) n=3, conventional therapy n=22
  4. crhPTH(1-84) n=97, conventional therapy n=490
  5. drhPTH(1-84) n=110, conventional therapy n=563